Global drugmakers refusing to conduct clinical trials in Russia

19 March 2022

Due to Russia’s military invasion of the Ukraine, global pharma companies are massively refusing to conduct clinical trials of their drugs in Russia, which means that the launch of these drugs in the local market will be impossible or at least seriously delayed, reports The Pharma Letter’s local correspondent.

So far, these plans have been confirmed by representatives of Pfizer (NYSE: PFE), Eli Lilly, AbbVie (NYSE: ABBV), Sanofi (Euronext: SAN) and Merck & Co (NYSE: MRK), as well as other companies.

For example, Pfizer, whose sales in Russia for 2021 according to data of the local analytical company DSM Group amounted to 52.8 billion roubles (~$496 million), said that it would transfer all current clinical trials to alternative sites outside of Russia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK